BioNanoTech aims to usher in new frontier in protein purification and drug discovery
Startup BioNanoTech has developed a patented platform technology for purifying proteins/antibodies across size ranges.
In particular, the company has developed a new class of Immobilization Metal Affinity Chromatography (IMAC) nanoresins.
“We are building something new at a new scale, and something that can do chemistry and physics on a scale that is more closely to what the target molecules are,” said John Harrold, chief scientific officer at BioNanoTech.
Do you have questions? Let us know how we can help! Contact us or subscribe to our newsletter and we will be in touch as soon as possible.